| Objective To observe the efficacy of spray inhalation with recombinant human interferon α2b injections in those children with respiratory syncytial viral (RSV) pneumonia. Methods 60 patients with infantile RSV pneumonia ever treated in our hospital between Sep 2013 and Aug 2014 were collected, and then divided into the control group and the study group by means of random number table, 30 cases in each group. Besides the conventional treatment given to the control group, children in the study group were given additional spray inhalation with recombinant human interferon α2b injections, 100 thousand IU/kg for once a day. After treatment of one week, the recovery time from such symptoms as cough, dyspnea and lung rale in the two groups were recorded, and their serum levels of TNF-α, IL-10 and IL-18 were also detected. Results After treatment of one week, the recovery time from such symptoms as cough, dyspnea and lung rale in the study group were all much shorter than those in the control group, with significant differences between them (P<0.05). The serum levels of TNF-α and IL-18 in the study group were significantly lower than those in the control group, but the IL-10 level was significantly higher than that in the control group[(19.74±6.88) ng/L vs (15.26±6.60) ng/L], and their differences were all statistically significant (P<0.05). The total effective rate in the study group (96.42%) was significantly higher than that in the control group (80.00%; P<0.05),the rate of adverse raction in the study group was 6.67%,but no significant different between the control group and the study group(P>0.05). Conclusion Administration of spray inhalation with recombinant human interferon α2b injections in treatment of patients with infantile RSV pneumonia could decrease their levels of inflammatory factors, with mild adverse reactions and remarkable clinical efficacy. |
